Greenwich Lifesciences Inc (GLSI) — Cash Flow-to-Debt Ratio
Greenwich Lifesciences Inc (GLSI) has a Cash Flow-to-Debt Ratio of -0.90x as of March 2026, meaning its operating cash flow of $-4.70 Million could theoretically repay -1% of its total liabilities ($5.24 Million) in one year. Check GLSI capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Greenwich Lifesciences Inc Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Greenwich Lifesciences Inc across 9 annual periods. Also explore GLSI current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Greenwich Lifesciences Inc (2017–2025)
Year-by-year debt coverage analysis for Greenwich Lifesciences Inc. For market capitalisation and broader financial context, see GLSI market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.92x | $-9.91 Million | $2.02 Million | ▼ -5.5% |
| 2024 | -4.66x | $-7.27 Million | $1.56 Million | ▲ +78.8% |
| 2023 | -22.01x | $-6.48 Million | $294.41K | ▲ +6.7% |
| 2022 | -23.58x | $-6.20 Million | $262.90K | ▼ -111.7% |
| 2021 | -11.14x | $-4.29 Million | $385.17K | ▼ -910.3% |
| 2020 | -1.10x | $-1.15 Million | $1.05 Million | ▼ -417.8% |
| 2019 | -0.21x | $-293.27K | $1.38 Million | ▼ -1795.0% |
| 2018 | -0.01x | $-114.95K | $10.23 Million | ▲ +20.4% |
| 2017 | -0.01x | $-120.85K | $8.56 Million | — |